Safety and Efficacy on Cell-based Therapy in Patients With Recent Large Acute Myocardial Infarction

Inclusion Criteria: * Be at least 18 years of age and no more than 80 years of age. * Acute ST-segment elevation MI * Symptoms suggestive of acute MI * ≥ 2mm ST-segment elevation in 2 or more precordial leads or ≥ 1mm in or more limb leads or new left bundle branch block * Time from symptom onset to enrollment \< 120 hours * Left ventricular dysfunction by contrast ventriculography or echocardiography * EF above 25 % and lower than 40% * Focal wall motion akinesis or dyskinesis * Clearly identifiable infarct artery * Patent infarct artery (TIMI flow grade 2 or 3) of ≥ 2 mm in diameter following successful stent placement Exclusion Criteria: * Planned treatment with bypass surgery or prior CABG * Multi-vessel PCI * Prior myocardial infarction by history or presence of pathologic Q-waves * Active cardiogenic shock: mechanical ventilation, IABP, or vasopressors/inotropes * Successful reperfusion \< 3 hrs from symptom onset * Prior MI or significant chronic heart failure * Pacemaker/defibrillator * Contraindication to MRI (metallic foreign body, claustrophobia, inability to lie flat) * Significant hepatic dysfunction or renal insufficiency (estimated creatinine clearance\<25 and/or serum Cr \>2.5 mg/dl) * Baseline hematocrit \< 30 * Pregnancy, or lactation/parturition within the past 30 days * Active or planned treatment with chemotherapy * Anticipated difficulty with 90-day follow-up * Evidence of a serious, active infection in the opinion of the investigator including, but not limited to subjects who are HIV, hepatitis B or C positive * Any known severe hematological disease, malignancy, systemic or life threatening disorder that would be incompatible with the trial * Previous enrollment in this trial * Participation in an investigational drug or device study within the past 30 days